SYNTHETIC DEMONSTRATION — no real student or patient. Not a medical device.

Medication

Wegovy vs. Ozempic: What's the Difference?

Wegovy and Ozempic contain the same active ingredient — semaglutide — but are FDA-approved for different conditions at different doses. Ozempic (up to 2 mg/week) is approved for type 2 diabetes. Wegovy (up to 2.4 mg/week) is approved for chronic weight management and, since 2024, for reducing cardiovascular risk in people with obesity or overweight. The higher Wegovy dose produces greater weight loss — roughly 15% of body weight in clinical trials.

Written by Gale Editorial · grounded in the cited clinical sources below · Updated 2026-06-15. How we write.

Drug facts

Generic name:
semaglutide
Class:
GLP-1 receptor agonist
Brand names:
Wegovy, Ozempic
How it's taken:
Subcutaneous injection, once weekly

Talk to a clinician

Gale can match you with a clinician licensed in your state — the honest cost shown before you book.

Find care →

Two brand names, one molecule

Wegovy and Ozempic are both brand names for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist manufactured by Novo Nordisk. They share the same active ingredient, the same injection device design, and the same once-weekly subcutaneous dosing schedule — but they carry different FDA approvals, different maximum doses, and, critically, different insurance coverage profiles 1.

Semaglutide mimics a gut hormone that the body releases after eating. It acts on GLP-1 receptors in the pancreas (stimulating insulin release when blood sugar is elevated), the stomach (slowing gastric emptying so food stays longer), and appetite centers in the brain (reducing hunger signals) 1. These overlapping effects lower blood sugar in people with type 2 diabetes and reduce calorie intake in people with or without diabetes.

FDA approvals and approved doses

| | Ozempic | Wegovy | |---|---|---| | Active ingredient | Semaglutide | Semaglutide | | FDA-approved use | Type 2 diabetes; CV risk in T2D; chronic kidney disease in T2D | Chronic weight management; CV risk reduction in obesity/overweight | | Maximum approved dose | 2 mg/week | 2.4 mg/week (injectable) | | Starting dose | 0.25 mg/week | 0.25 mg/week | | FDA approval year | 2017 (diabetes); 2022 (2 mg dose) | 2021 (weight loss); 2024 (cardiovascular) |

Ozempic received FDA approval in 2017 for glycemic control in adults with type 2 diabetes. The 2 mg dose was added in 2022. Ozempic also carries approved indications for reducing cardiovascular risk in people with T2D and for slowing chronic kidney disease progression 1.

Wegovy was approved in 2021 for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity. In March 2024, a second indication was granted: reducing the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and obesity or overweight — making it the first weight-loss drug approved for a cardiovascular benefit 2.

How the higher Wegovy dose translates to greater weight loss

The 0.4 mg difference in weekly maintenance dose — Wegovy's 2.4 mg versus Ozempic's 2 mg maximum — produces a meaningful difference in weight loss outcomes.

In the STEP 1 trial, the landmark phase 3 study of semaglutide 2.4 mg in adults without diabetes, participants lost a mean of 14.9% of body weight over 68 weeks, compared with 2.4% in the placebo group. Eighty-six percent of semaglutide recipients lost at least 5% of body weight; 32% lost 20% or more 3.

Across the full STEP clinical program, the 2.4 mg weekly dose produced mean weight reductions of 9.6% in people with type 2 diabetes (STEP 2), 16.0% with intensive behavioral therapy (STEP 3), and 17.4% cumulative weight loss in participants who had already been on semaglutide for one year (STEP 4) 4.

In Ozempic's diabetes trials, weight loss is a secondary outcome — patients with type 2 diabetes typically see 5–10% body weight reduction at the 1 mg and 2 mg doses, reflecting both the lower dose and the different metabolic context.

For the cardiovascular indication, the SELECT trial enrolled 17,604 adults with preexisting cardiovascular disease but without diabetes and a BMI of 27 or higher. Participants assigned to semaglutide 2.4 mg had a 20% lower rate of major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, or nonfatal stroke) compared with placebo over a mean follow-up of 39.8 months 2.

Off-label Ozempic for weight loss: what it means

A prescriber can legally write Ozempic for weight loss in a patient without type 2 diabetes — this is off-label use, common and legally permitted in medicine. It became widespread during Wegovy's 2022–2023 supply shortages. Two practical limits apply: Ozempic tops out at 2 mg/week (Wegovy reaches 2.4 mg, producing greater weight loss) 3, and most plans that cover Ozempic do so for its on-label diabetes indication rather than for off-label weight management — the same active ingredient is covered far more often when prescribed for diabetes than for weight loss 5. Wegovy remains the on-label route for weight loss.

Cost and insurance coverage

Cost is one of the most consequential practical differences between the two medications.

Self-pay pricing (mid-2026): Novo Nordisk lowered its NovoCare Pharmacy standard self-pay price from $499 to $349/month for most Wegovy injectable doses (0.25, 0.5, 1, 1.7, and 2.4 mg) and for most Ozempic doses; Ozempic 2 mg remains $499/month. New self-pay patients pay an introductory $199/month for the two lowest doses for the first two months 7. These cash prices sit well below the historical list price of roughly $1,349/month for Wegovy.

A further list-price cut is announced, not yet in effect: In February 2026, Novo Nordisk said it would reduce the U.S. list price (WAC) for Wegovy, Ozempic, and Rybelsus to approximately $675 effective January 1, 2027 — an estimated ~50% reduction for Wegovy and ~35% for Ozempic. The company stated this list-price change does not affect direct-to-patient self-pay prices 8. (Figure is a manufacturer-announced future estimate, not a current price.)

Insurance coverage: Coverage tracks the indication, not the molecule. In a KFF analysis of 2024 ACA Marketplace plans, Ozempic (approved for diabetes) was covered by 82% of Marketplace prescription-drug plans, while Wegovy (approved for weight loss) was covered by just 1% — even though both are semaglutide 5. Employer coverage for weight loss is also limited but somewhat broader: in KFF's 2025 Employer Health Benefits Survey, GLP-1 drugs used primarily for weight loss were covered by 16% of firms with 200–999 workers, 30% of firms with 1,000–4,999 workers, and 43% of the largest firms (5,000+ workers) 6. Plans that do cover Wegovy typically require prior authorization with BMI documentation and evidence of a qualifying comorbidity.

Medicare Part D has historically excluded weight-loss drugs; Wegovy is partially covered for beneficiaries with established cardiovascular disease under the 2024 SELECT indication 2, but not for weight management alone. Medicaid varies by state.

Savings programs: Commercially insured patients may pay as little as $25/month for Wegovy through the NovoCare savings card (maximum savings $100/month). Government beneficiaries (Medicare, Medicaid) are excluded from manufacturer savings cards 7.

Side effects: what the two drugs share

Because Wegovy and Ozempic are the same molecule, their side effect profiles are nearly identical and class-typical for GLP-1 receptor agonists.

Common (affecting more than 1 in 10 people): - Nausea — most frequent, especially during dose escalation - Diarrhea - Vomiting - Constipation - Abdominal discomfort

Gastrointestinal side effects are the leading reason people discontinue. In the STEP 1 trial, 4.5% of participants stopped semaglutide due to GI events (vs. 0.8% on placebo) 3.

Less common: - Fatigue - Injection-site reactions - Heart rate increase (average 5–10 bpm) - Gallbladder disease, including gallstones

Rare but serious: - Pancreatitis (severe upper abdominal pain radiating to the back) - Acute kidney injury (often from dehydration during GI illness)

FDA Boxed Warning: Both drugs carry a black-box warning based on rodent studies in which semaglutide caused dose-dependent thyroid C-cell tumors. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Post-marketing human surveillance has not established a confirmed causal link 1.

Neither drug is recommended during pregnancy.

How to choose — and what to bring to the clinician conversation

The choice between the two depends on the primary clinical goal and insurance coverage:

  • Type 2 diabetes: Ozempic is the on-label choice with broad coverage and established cardiovascular and kidney-protection data 1.
  • Weight loss without diabetes: Wegovy is the on-label choice reaching the higher 2.4 mg dose with the strongest weight-loss evidence 3.
  • Cardiovascular disease with obesity (no diabetes): Wegovy carries a direct 2024 FDA indication for MACE reduction based on SELECT 2, which may support prior authorization arguments.
  • Cost barrier: At the NovoCare self-pay price of $349/month, Wegovy is now meaningfully more accessible than at historical list prices 7.

A primary care clinician or obesity medicine specialist can assess eligibility, submit prior authorization, and document the clinical basis for whichever medication is appropriate.

Common questions

Are Wegovy and Ozempic the same drug?

They contain the same active ingredient — semaglutide — at the same injection frequency (once weekly). The difference is their FDA-approved indication and maximum dose. Ozempic (up to 2 mg/week) is approved for type 2 diabetes. Wegovy (up to 2.4 mg/week) is approved for chronic weight management and cardiovascular risk reduction in people with obesity or overweight.

Why does Wegovy cause more weight loss than Ozempic?

Wegovy's maintenance dose of 2.4 mg per week is higher than Ozempic's maximum of 2 mg per week. Higher doses produce greater appetite suppression. In the STEP 1 trial, Wegovy 2.4 mg produced a mean weight loss of 14.9% of body weight over 68 weeks. Ozempic's weight effects — a secondary outcome in diabetes trials — typically fall in the 5–10% range.

Can a doctor prescribe Ozempic for weight loss if I don't have diabetes?

Yes. Prescribing Ozempic off-label for weight loss in people without type 2 diabetes is legal and not uncommon. However, the same active ingredient is covered far more often when prescribed for diabetes than for off-label weight management, so out-of-pocket cost is a significant factor. Wegovy is the on-label choice for weight loss.

Does insurance cover Wegovy?

Coverage is inconsistent and depends on the indication, not the molecule. In a KFF analysis of 2024 ACA Marketplace plans, Wegovy (approved for weight loss) was covered by just 1% of plans, versus 82% for Ozempic (approved for diabetes). Employer coverage for weight loss is somewhat broader but still limited — KFF's 2025 employer survey found GLP-1 weight-loss coverage at 16% of firms with 200–999 workers, rising to 43% of firms with 5,000+ workers. Plans that do cover Wegovy typically require prior authorization with documentation of qualifying BMI and comorbidities. Medicare covers Wegovy only for patients with established cardiovascular disease. Medicaid coverage varies by state.

How much does Wegovy cost without insurance?

Novo Nordisk lowered its standard NovoCare Pharmacy self-pay price to $349/month for most Wegovy injectable doses (down from $499), with an introductory $199/month for the two lowest doses for the first two months. That is well below the historical list price of roughly $1,349/month. Separately, the company announced a list-price reduction to about $675 effective January 1, 2027 — an announced future change that does not affect self-pay prices. Commercially insured patients with Wegovy coverage may pay as little as $25/month with the NovoCare savings card.

What are the risks of taking semaglutide (either brand)?

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, and constipation — most pronounced during dose escalation. Both drugs carry an FDA boxed warning about thyroid C-cell tumors observed in rodents; they are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN 2). Rare serious risks include pancreatitis and gallbladder disease.

Related conditions

Condition/Glp 1 Muscle Loss

Related medications

Drug/Semaglutide · Drug/Wegovy · Drug/Ozempic · Drug/Tirzepatide · Drug/Semaglutide Vs Tirzepatide · Drug/Glp 1 Agonists · Drug/Wegovy Cost · Drug/Ozempic Cost

Specialties

Specialty/Primary Care

Talk to a clinician

Say what's going on in your own words. Gale finds a clinician licensed in your state and shows the real cost before you book.

Find care →

When to seek care

  • —Severe or persistent abdominal pain, especially radiating to the back — possible pancreatitis
  • —Signs of a serious allergic reaction: rash, swelling of the face or throat, difficulty breathing
  • —Vision changes after starting semaglutide — report to a clinician
  • —Signs of dehydration from vomiting or diarrhea (extreme thirst, dark urine, dizziness)
  • —Rapid worsening of symptoms that were previously well controlled

Call 911 or go to an emergency room for severe abdominal pain, difficulty breathing, or throat swelling.

General health information, not medical advice. Synthetic demonstration content.

References

  1. 1.Rath T et al. (StatPearls authors); reviewed by NCBI (2024). Semaglutide. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. link ✓Mechanism of action of semaglutide as a GLP-1 receptor agonist; FDA approval dates and indications for Ozempic (type 2 diabetes, up to 2 mg/week) and Wegovy (chronic weight management, 2.4 mg/week); black-box warning for thyroid C-cell tumors and MTC/MEN2 contraindication
  2. 2.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. (SELECT Trial Investigators) (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. doi:10.1056/NEJMoa2307563 ✓SELECT trial: semaglutide 2.4 mg reduced MACE by 20% (HR 0.80) vs. placebo over 39.8 months in 17,604 adults with CVD and obesity/overweight but without diabetes; basis for 2024 FDA cardiovascular indication for Wegovy
  3. 3.Wilding JPH, Batterham RL, Calanna S, et al. (STEP 1 Study Group) (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. doi:10.1056/NEJMoa2032183 ✓STEP 1 trial: semaglutide 2.4 mg produced 14.9% mean body weight loss vs. 2.4% placebo over 68 weeks; 86.4% of participants lost ≥5% body weight; 4.5% discontinued due to GI events
  4. 4.Colin IM, Gérard KM (2022). Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?. touchREVIEWS in Endocrinology. doi:10.17925/EE.2022.18.1.35 ✓STEP program cross-trial results: STEP 2 (9.6% weight loss with T2D), STEP 3 (16.0% with intensive behavioral therapy), STEP 4 (17.4% cumulative); 32% of STEP 1 participants lost ≥20% body weight
  5. 5.KFF (Kaiser Family Foundation) (2024). Costly GLP-1 Drugs are Rarely Covered for Weight Loss by Marketplace Plans. KFF — analysis of 2024 ACA Marketplace plan data. link ✓Of 2024 ACA Marketplace prescription-drug plans, Wegovy (weight loss) is covered by 1% and Ozempic (diabetes) by 82% — despite both being semaglutide; coverage tracks indication, not molecule
  6. 6.KFF (Kaiser Family Foundation) (2025). 2025 Employer Health Benefits Survey. KFF. link ✓GLP-1 drugs used primarily for weight loss covered by 16% of firms with 200–999 workers, 30% of firms with 1,000–4,999 workers, and 43% of firms with 5,000+ workers in 2025
  7. 7.Novo Nordisk (press release) (2025). Novo Nordisk launches introductory self-pay offer for Wegovy and Ozempic for $199 per month. PR Newswire. link ✓NovoCare Pharmacy standard self-pay price lowered from $499 to $349/month for most Wegovy and Ozempic doses (Ozempic 2 mg remains $499); $199/month introductory offer for the two lowest doses for the first two months; $25/month NovoCare savings-card price for commercially insured patients (Nov 17, 2025)
  8. 8.Novo Nordisk (press release) (2026). Novo Nordisk announces significant reduction in US list price for Wegovy, Ozempic, and Rybelsus (semaglutide medicines). PR Newswire. link ✓Announced (Feb 24, 2026) US list-price (WAC) reduction to approximately $675 for Wegovy, Ozempic, and Rybelsus effective January 1, 2027 (~50% reduction for Wegovy, ~35% for Ozempic); states the list-price change does not affect direct-to-patient self-pay prices

https://www.gale.care/drugs/wegovy-vs-ozempic · 8 sources. General health information, not medical advice — synthetic demonstration content.